ETF盘中资讯｜跨国药企发起降价潮？港股通创新药逆市走低，520880溢价高企！机构力挺国产创新药：重点关注2026年Q1

Core Viewpoint - The Hong Kong stock market opened positively, with the Hang Seng Index rising, but the innovative drug sector unexpectedly declined, indicating potential volatility in this segment [1]. Group 1: Market Performance - The Hang Seng Index showed a rise, with the Hang Seng Technology Index increasing by over 2% at one point [1]. - The Hong Kong Stock Connect innovative drug ETF (520880) fell by more than 1.5% during trading, with major stocks like CSPC Pharmaceutical Group and CanSino Biologics dropping over 1% [1]. Group 2: Investment Sentiment - Despite the decline, the Hong Kong Stock Connect innovative drug ETF (520880) continued to trade at a premium, suggesting that there may be investors looking to buy on dips [2]. - Analysts remain optimistic about domestic innovative drugs, noting that the past two years have been significant for Chinese innovative drugs entering international markets, with record highs in both the number and value of licensing deals [3]. Group 3: Future Outlook - The industry is expected to see continued positive catalysts in 2026, including major industry conferences, significant business development transactions, and breakthroughs in new technologies [3]. - The innovative drug sector has been in a phase of adjustment since September, with risks being sufficiently released, leading to improved cost-effectiveness for investments [3]. Group 4: ETF Characteristics - The Hong Kong Stock Connect innovative drug ETF (520880) has a significant concentration in leading companies, with the top ten stocks accounting for over 72% of its weight, indicating a strong representation of the innovative drug sector [4]. - The ETF is designed to exclude CXO companies, focusing solely on innovative drug firms, which enhances its appeal to investors seeking pure exposure to this segment [3][4].